Can Lunesta and Belsomra Be Combined?
Combining Lunesta (eszopiclone) and Belsomra (suvorexant) is not recommended based on FDA labeling, which explicitly states that "the use of BELSOMRA with other drugs to treat insomnia is not recommended." 1
Key Safety Concerns
The FDA label for Belsomra clearly warns that when combined with other CNS depressants, dosage reduction of BELSOMRA and/or the other drug(s) may be necessary because of potentially additive effects 1. Since both medications are CNS depressants used for insomnia:
- Eszopiclone works as a GABA receptor agonist (benzodiazepine receptor agonist)
- Suvorexant works as a dual orexin receptor antagonist (DORA)
While they have different mechanisms of action, combining them creates additive CNS depressant effects that increase risks of:
- Excessive daytime somnolence
- Impaired driving ability and falls
- Prolonged next-day impairment
- Increased risk of complex sleep behaviors
Clinical Guideline Perspective
The American Academy of Sleep Medicine guidelines 2 provide weak recommendations for both medications as monotherapy:
- Eszopiclone: Suggested for sleep onset and sleep maintenance insomnia (2-3 mg doses)
- Suvorexant: Suggested for sleep maintenance insomnia (10-20 mg doses)
However, these guidelines evaluate each agent versus no treatment—not in combination with other hypnotics.
Practical Clinical Approach
If a patient is not responding adequately to one agent:
- Optimize the current medication first - Ensure proper dosing, timing (30 minutes before bed with 7+ hours for sleep), and that it's not taken with food
- Switch, don't combine - Transition from one agent to the other using a cross-taper approach 3
- Add CBT-I instead - Guidelines consistently recommend cognitive behavioral therapy for insomnia over polypharmacy 4
Switching Protocol (if needed):
- Gradually reduce the first medication by 10-25% weekly while introducing the second agent 3
- Never abruptly discontinue, especially with eszopiclone (GABA-ergic agent)
- Monitor closely for withdrawal symptoms or rebound insomnia
Critical Caveats
The FDA contraindication against combining insomnia medications with Belsomra is absolute and takes precedence over any theoretical benefit from dual mechanisms. The risk of serious CNS depression, falls (particularly in elderly), motor vehicle accidents, and complex sleep behaviors outweighs potential therapeutic gains.
If insomnia remains refractory to monotherapy with either agent, the appropriate next step is referral to sleep medicine for comprehensive evaluation and consideration of CBT-I, not medication stacking.